MADISON, Wis. – Voximetry, a pioneer in advanced technology to enable personalized treatments for late-stage cancer patients, announced today that it has received a Medical Device Single Audit Program (MDSAP) Certificate. This brings Voximetry one step closer to market clearance for clinical use of Torch Dose Assessment software in Canada and Australia.
“Access to new markets is key to Voximetry’s mission of making personalized care available to every patient and care provider,” said Sue Wallace, CEO of Voximetry. “Securing MDSAP certification is an important milestone in successfully navigating the commercial growth phase the Company.”
The company is also poised for a CE mark clearance for European commercialization in early 2025.
ABOUT VOXIMETRY
Voximetry is committed to enabling personalized and effective theranostic treatment options for patients worldwide through wide-ranging collaboration, deep scientific expertise, and technology-forward progress. Based in Madison, Wisconsin, Voximetry is a Healthtech software and services company pioneering patient-specific radiopharmaceutical treatment planning (RPT) in advanced stage cancer patients.
ABOUT TORCH
Torch® Dose Assessment software is a proprietary product developed by Voximetry and approved for clinical use by the FDA. Torch design and development continues to be supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R43CA221491 and 2R44CA291564. The product is solely the responsibility of Voximetry and does not represent the official views of the National Institutes of Health.